AlphAIAlphAI — Financial news for AI agents
stocktitan.net$EVAX

In a melanoma trial, 89% of targets in a personalized cancer vaccine triggered an immune response.

Evaxion A/S (NASDAQ: EVAX) reported new biomarker data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. The data showed 89% of vaccine targets triggered an immune response, validating the company's AI-Immunology™ platform. The findings were presented at the SITC 2026 Annual Meeting.

Original reporting
stocktitan.net
Published Nov 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 4:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$EVAX
Bullish
high confidence
Mentioned
$EVAX
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$EVAXBullishMed
01

Why it matters

The biomarker data strengthens the scientific credibility of the platform and may accelerate partnership discussions, influencing the stock’s short‑term trajectory.

02

Market read

First‑report of robust phase‑2 data for a personalized cancer vaccine, likely to move EVAX shares and influence AI‑biotech sentiment.

03

What to watch

The data were presented at a conference; actual regulatory impact and commercial partnership timelines remain uncertain.

Relevance 8/10Novelty 9/10Timing: today

Background

Evaxion A/S is a clinical‑stage TechBio firm developing AI‑designed immunotherapies. The EVX‑01 vaccine combines its AI‑Immunology™ platform with pembrolizumab in a melanoma trial.

Company-level read

Ticker impact

$EVAXBullishHigh confidence
Context

Evaxion disclosed new phase‑2 biomarker data showing 89% target precision and strong immune responses for its personalized melanoma vaccine EVX‑01.

Expected impact

upward pressure as the market prices in the strong immune‑response results.

Evidence & confidence

Phase‑2 data with statistically significant immune markers is material for a clinical‑stage biotech and often triggers short‑term buying.

Market effects

Sector

Reinforces confidence in AI‑driven personalized cancer vaccines, potentially benefiting peer biotech firms using similar platforms.

Regional

European biotech indices may see modest gains as a Copenhagen‑based company reports strong data.

Global

Adds to the broader narrative of AI‑enabled drug discovery gaining traction worldwide.

Counterpoint

What could challenge this read

Investors may question durability of immune responses and await longer‑term efficacy data before committing.

Key entities

  • company
    Evaxion A/S

    Clinical‑stage biotech developing AI‑driven cancer vaccines.

  • company
    Merck & Co., Inc.

    Provider of pembrolizumab (Keytruda) used in the trial.

Read at source← All news

StoryEvaxion reports 89% immune response rate for personalized melanoma vaccine in phase‑2 trial

Also covered by

1 outlet

Related articles

$EVAXMedAI 8/10

Evaxion: New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01

Evaxion A/S (NASDAQ: EVAX) presented phase 2 trial data for its personalized cancer vaccine EVX-01, showing strong immune responses in advanced melanoma patients. The data, shared at the SITC 2026 Annual Meeting, includes 89% vaccine target precision and sustained T-cell responses. Evaxion's AI-Immunology platform demonstrated strong predictive performance, with significant association between predictions and actual T-cell responses.

finanznachrichten.de
$EVAXMedAI 9/10

Evaxion presents phase 2 cancer vaccine biomarker data at SITC

Evaxion A/S (NASDAQ:EVAX) presented phase 2 trial data for its cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer Annual Meeting. The data showed significant T-cell responses and a strong association between its AI-Immunology platform's predictions and actual immune responses. The trial reported an Objective Response Rate of 75% in advanced melanoma patients.

investing.com
$EVAXMed

Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting

Evaxion A/S (NASDAQ: EVAX) will present new data on EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML), at the ASH 2026 Meeting. The data validate EVX-04's potential, showing broad patient coverage and immune response induction in preclinical models. EVX-04 targets non-conventional endogenous retrovirus (ERV) tumor antigens, selected using Evaxion's AI-Immunology platform.

finanznachrichten.de
$EVAXMedAI 8/10

Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

Evaxion (NASDAQ: EVAX) will present new biomarker data from its phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting. The trial, involving advanced melanoma patients, showed a 75% objective response rate. EVX-01 is designed with Evaxion's AI-Immunology platform and is being evaluated as a treatment for advanced melanoma.

finanznachrichten.de
$EVAXHighAI 8/10

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Evaxion A/S (NASDAQ: EVAX) reported 3-year data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. The trial showed 89% of vaccine neoantigens generated specific T-cell responses, with sustained immune and clinical responses. The data will be presented at the ESMO 2026 Congress. Evaxion maintains a cash runway into 2027.

finanznachrichten.de